INCYTE
Incyte 2013 Annual Report
to Stockholders
Jakafi® (ruxolitinib)
Prescribing Information

is a biopharmaceutical company focused on discovering, developing and commercializing proprietary small molecule drugs for oncology and inflammation.

News
FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted
Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies
Jakafi® (ruxolitinib)
IncyteCARES
Connecting to Access, Reimbursement, Education and Support
To learn more, click here